Cresco Labs Inc.
CRLBF
$0.72
-$0.0412-5.41%
| Weiss Ratings | CRLBF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | E | |||
| Rating Factors | CRLBF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Good | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Good | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | CRLBF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.60 | |||
| Price History | CRLBF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -18.16% | |||
| 30-Day Total Return | -24.34% | |||
| 60-Day Total Return | -33.02% | |||
| 90-Day Total Return | -55.83% | |||
| Year to Date Total Return | -24.13% | |||
| 1-Year Total Return | -54.14% | |||
| 2-Year Total Return | -62.54% | |||
| 3-Year Total Return | -87.28% | |||
| 5-Year Total Return | -77.39% | |||
| 52-Week High % Change | -70.72% | |||
| 52-Week Low % Change | 6.42% | |||
| Price | CRLBF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $2.60 | |||
| 52-Week Low Price | $0.72 | |||
| 52-Week Low Price (Date) | Mar 05, 2025 | |||
| 52-Week High Price (Date) | Apr 30, 2024 | |||
| Valuation | CRLBF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 264.26M | |||
| Enterprise Value | 682.68M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.20 | |||
| Earnings Per Share Growth | -81.89% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 0.36 | |||
| Price/Book (Q) | 0.58 | |||
| Enterprise Value/Revenue (TTM) | 0.94 | |||
| Price | $0.72 | |||
| Enterprise Value/EBITDA (TTM) | 3.71 | |||
| Enterprise Value/EBIT | 5.77 | |||
| Market Cap Category | Micro Cap | |||
| Dividends and Shares | CRLBF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 347.36M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -0.30% | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | CRLBF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 312 410 8226 | |||
| Address | 400 West Erie Street Chicago, IL 60654 | |||
| Website | www.crescolabs.com | |||
| Country | United States | |||
| Year Founded | 1990 | |||
| Profitability | CRLBF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | 16.29% | |||
| Profit Margin | -9.28% | |||
| Management Effectiveness | CRLBF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | 5.32% | |||
| Return on Equity | -- | |||
| Income Statement | CRLBF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 726.35M | |||
| Total Revenue (TTM) | 726.35M | |||
| Revenue Per Share | $2.09 | |||
| Gross Profit (TTM) | 366.26M | |||
| EBITDA (TTM) | 183.77M | |||
| EBIT (TTM) | 118.33M | |||
| Net Income (TTM) | -67.43M | |||
| Net Income Avl. to Common (TTM) | -67.43M | |||
| Total Revenue Growth (Q YOY) | -4.53% | |||
| Earnings Growth (Q YOY) | 93.22% | |||
| EPS Diluted (TTM) | -0.20 | |||
| EPS Diluted Growth (Q YOY) | 91.15% | |||
| Balance Sheet | CRLBF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 153.30M | |||
| Cash Per Share (Q) | $0.44 | |||
| Total Current Assets (Q) | 311.92M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 365.37M | |||
| Current Ratio (Q) | 1.967 | |||
| Book Value Per Share (Q) | $1.31 | |||
| Total Assets (Q) | 1.38B | |||
| Total Current Liabilities (Q) | 158.57M | |||
| Total Debt (Q) | 690.45M | |||
| Total Liabilities (Q) | 1.02B | |||
| Total Common Equity (Q) | 456.88M | |||
| Cash Flow | CRLBF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -19.61M | |||
| Cash from Financing (TTM) | -33.23M | |||
| Net Change in Cash (TTM) | 46.79M | |||
| Levered Free Cash Flow (TTM) | 70.14M | |||
| Cash from Operations (TTM) | 99.69M | |||
